BALTIMORE, Aug. 3, 2012 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has issued research coverage of Immunovative, Inc. (OTCBB:IMUN), the exclusive licensee of a novel portfolio of immunotherapy drug products to treat cancer.
Immunovative, Inc. is the exclusive worldwide licensee of any product commercialization covered under Israel-based Immunovative Therapies, Ltd.'s (ITL) current issued and pending patent application portfolio. ITL has demonstrated in Phase I/II clinical trials that its novel, targeted immunotherapy technology that uses the body's own immune system to treat metastatic breast cancer (MBC), was able to eliminate the need for chemotherapy and the risk of other lethal toxicity through other treatment methods.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.
"In our view, the ITL technology is poised to revolutionize the way we treat cancer. The Company's groundbreaking therapy has proven in clinical trials to substantially increase survival rate in patients stricken with MBC while eliminating lethal toxicity, versus the toxicity that occurs in standard approaches to treatment. Future trials could confirm previous trial results and result in fast-track status with the FDA. Plus, the technology appears to have indications for a number of other cancers which should prompt additional trials down the road as well."
To view a summary of the report or download the report in its entirety, please visit
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Immunovative, Inc.: Immunovative, Inc. (OTCBB:IMUN) On December 15, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. For more information, visit the Company's website at www.imun.com